Identification of the NS5B S282T resistant variant and two novel amino acid substitutions that affect replication capacity in hepatitis C virus-infected patients treated with mericitabine and danoprevir.

Abstract excerpt

Baseline and posttreatment samples from hepatitis C virus (HCV) genotype (GT) 1-infected patients who received a combination of danoprevir and mericitabine from a phase II clinical study (INFORM-SVR) were analyzed. In addition to resistance monitoring, sequencing and phenotypic assays were combin...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cyclopropanes
• Share to Deoxycytidine
• Share to Drug Therapy, Combination